127 related articles for article (PubMed ID: 33619933)
1. Major Thalassemia, Screening or Treatment: An Economic Evaluation Study in Iran.
Esmaeilzadeh F; Ahmadi B; Vahedi S; Barzegari S; Rajabi A
Int J Health Policy Manag; 2022 Jul; 11(7):1112-1119. PubMed ID: 33619933
[TBL] [Abstract][Full Text] [Related]
2. Cost Effectiveness of Hematopoietic Stem Cell Transplantation Compared with Transfusion Chelation for Treatment of Thalassemia Major.
John MJ; Jyani G; Jindal A; Mashon RS; Mathew A; Kakkar S; Bahuguna P; Prinja S
Biol Blood Marrow Transplant; 2018 Oct; 24(10):2119-2126. PubMed ID: 29673692
[TBL] [Abstract][Full Text] [Related]
3. Cost-utility of new film-coated tablet formulation of deferasirox vs deferoxamine among major beta-thalassemia patients in Iran.
Saiyarsarai P; Khorasani E; Photogeraphy H; Ghaffari Darab M; Seyedifar M
Medicine (Baltimore); 2020 Jul; 99(28):e20949. PubMed ID: 32664096
[TBL] [Abstract][Full Text] [Related]
4. Economic Burden of Thalassemia Major in Iran, 2015.
Esmaeilzadeh F; Azarkeivan A; Emamgholipour S; Akbari Sari A; Yaseri M; Ahmadi B; Ghaffari M
J Res Health Sci; 2016; 16(3):111-115. PubMed ID: 27840337
[TBL] [Abstract][Full Text] [Related]
5. Iron-chelating therapies in a transfusion-dependent thalassaemia population in Thailand: a cost-effectiveness study.
Luangasanatip N; Chaiyakunapruk N; Upakdee N; Wong P
Clin Drug Investig; 2011; 31(7):493-505. PubMed ID: 21627338
[TBL] [Abstract][Full Text] [Related]
6. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
[TBL] [Abstract][Full Text] [Related]
7. Cost utility analysis of reduced intensity hematopoietic stem cell transplantation in adolescence and young adult with severe thalassemia compared to hypertransfusion and iron chelation program.
Sruamsiri R; Chaiyakunapruk N; Pakakasama S; Sirireung S; Sripaiboonkij N; Bunworasate U; Hongeng S
BMC Health Serv Res; 2013 Feb; 13():45. PubMed ID: 23379888
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of embryo transfer strategies: a decision analytic model using long-term costs and consequences of singletons and multiples born as a consequence of IVF.
van Heesch MM; van Asselt AD; Evers JL; van der Hoeven MA; Dumoulin JC; van Beijsterveldt CE; Bonsel GJ; Dykgraaf RH; van Goudoever JB; Koopman-Esseboom C; Nelen WL; Steiner K; Tamminga P; Tonch N; Torrance HL; Dirksen CD
Hum Reprod; 2016 Nov; 31(11):2527-2540. PubMed ID: 27907897
[TBL] [Abstract][Full Text] [Related]
9. Lifetime cost-utility analyses of deferasirox in beta-thalassaemia patients with chronic iron overload: a UK perspective.
Karnon J; Tolley K; Vieira J; Chandiwana D
Clin Drug Investig; 2012 Dec; 32(12):805-15. PubMed ID: 23026844
[TBL] [Abstract][Full Text] [Related]
10. Cost-utility analysis of deferiprone for the treatment of β-thalassaemia patients with chronic iron overload: a UK perspective.
Bentley A; Gillard S; Spino M; Connelly J; Tricta F
Pharmacoeconomics; 2013 Sep; 31(9):807-22. PubMed ID: 23868464
[TBL] [Abstract][Full Text] [Related]
11. Cost-utility analysis of oral deferasirox versus infusional deferoxamine in transfusion-dependent β-thalassemia patients.
Keshtkaran A; Javanbakht M; Salavati S; Mashayekhi A; Karimi M; Nuri B
Transfusion; 2013 Aug; 53(8):1722-9. PubMed ID: 23241074
[TBL] [Abstract][Full Text] [Related]
12. A pharmaco-economic evaluation of deferasirox for treating patients with iron overload caused by transfusion-dependent thalassemia in Taiwan.
Ho WL; Chung KP; Yang SS; Lu MY; Jou ST; Chang HH; Yang YL; Lin DT; Lin KH
J Formos Med Assoc; 2013 Apr; 112(4):221-9. PubMed ID: 23537869
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspective.
Delea TE; Sofrygin O; Thomas SK; Baladi JF; Phatak PD; Coates TD
Pharmacoeconomics; 2007; 25(4):329-42. PubMed ID: 17402805
[TBL] [Abstract][Full Text] [Related]
14. Lifetime Cost Effectiveness of Phenylketonuria Screening National Program in Iran.
Heidari A; Arab M; Damari B
Iran J Public Health; 2021 Oct; 50(10):2105-2110. PubMed ID: 35223578
[TBL] [Abstract][Full Text] [Related]
15. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
Davis S; Simpson E; Hamilton J; James MM; Rawdin A; Wong R; Goka E; Gittoes N; Selby P
Health Technol Assess; 2020 Jun; 24(29):1-314. PubMed ID: 32588816
[TBL] [Abstract][Full Text] [Related]
16. A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context.
Buxton M; Caine N; Chase D; Connelly D; Grace A; Jackson C; Parkes J; Sharples L
Health Technol Assess; 2006 Aug; 10(27):iii-iv, ix-xi, 1-164. PubMed ID: 16904046
[TBL] [Abstract][Full Text] [Related]
17. Reverse Total Shoulder Arthroplasty Is the Most Cost-effective Treatment Strategy for Proximal Humerus Fractures in Older Adults: A Cost-utility Analysis.
Abdel Khalik H; Humphries B; Zoratti M; Axelrod D; Kruse C; Ristevski B; Rajaratnam K; Gardner M; Tarride JÉ; Johal H
Clin Orthop Relat Res; 2022 Oct; 480(10):2013-2026. PubMed ID: 35507306
[TBL] [Abstract][Full Text] [Related]
18. Economic evaluation of point of care universal newborn screening for glucose-6-Phosphate dehydrogenase deficiency in United States.
Vidavalur R; Bhutani VK
J Matern Fetal Neonatal Med; 2022 Dec; 35(25):5745-5753. PubMed ID: 33627013
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States.
Chatterjee A; Shapouri S; Manzoor BS; Ravelo A; Sail K; Qendri V; van de Wetering G; Davids MS
J Manag Care Spec Pharm; 2021 Nov; 27(11):1532-1544. PubMed ID: 34714110
[No Abstract] [Full Text] [Related]
20. Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA.
Mauskopf J; Brogan A; Martin S; Smets E
Pharmacoeconomics; 2010; 28 Suppl 1():83-105. PubMed ID: 21182346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
